Colonoscopy Prep Is Not as Bad as You Think
In his op-ed 'Colonoscopy Prep Is Worse Than IKEA' (June 3), Jim Sollisch gives readers the impression that there has been a universal shift to a three-day bowel preparation for colonoscopies. This isn't the case.
There are a variety of bowel-prep options, each of which comes with specific steps for patients to follow to ensure the colon is fully cleansed before the procedure. A patient navigation system can allow patients to have their questions answered, which may help optimize adherence. Gastroenterologists recommend a bowel prep alongside diet adjustments that might work best. This is often limited to dietary changes the day before the colonoscopy based on the newest recommendations by the U.S. Multi-Society Task Force on Colorectal Cancer to optimize bowel preparations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)
HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will be presented at the 85th Scientific Sessions of American Diabetes Association (ADA) in Chicago, U.S. Details of the Poster Presentations Poster Number: 750-P Abstract Title: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) Poster Number: 847-P Abstract Title: ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model Session Type: General Poster Session Location: Poster Hall (Hall F1) Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time) About ASC30 ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044. About ASC47 ASC47 is an adipose-targeted, ultra-long-acting subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue. Topline data from its Phase Ib single subcutaneous injection studies in Australia in participants with elevated low-density lipoprotein cholesterol (LDL-C) (NCT06427590) have been released. The Phase I clinical trial of ASC47 in combination with semaglutide for the treatment of obesity (NCT06972992) is ongoing in the U.S., and the first participants were dosed in May 2025. About the American Diabetes Association (ADA) Established in 1940, the American Diabetes Association (ADA) is dedicated to preventing and curing diabetes and to improving the lives of all people affected by diabetes. It has grown into one of the foremost nonprofit organizations in diabetes advocacy around the world. Its annual Scientific Sessions set the agenda for clinical practice and research innovation. The 85th Scientific Sessions of ADA will be held in Chicago, U.S. from June 20 to 23, 2025. About Ascletis Pharma Inc. Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange ( covering the entire value chain from discovery and development to GMP manufacturing. Led by a management team with deep expertise and a proven track record, Ascletis is focused on metabolic diseases by addressing unmet medical needs from a global perspective. Ascletis has multiple clinical stage drug candidates in its metabolic disease pipeline. For more information, please visit Contact： Peter Vozzo ICR Healthcare 443-231-0505 (U.S.) Ascletis Pharma Inc. PR and IR teams +86-181-0650-9129 (China) pr@ ir@ View original content: SOURCE Ascletis Pharma Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Samsung Bioepis Enters into a Strategic Partnership with NIPRO for Commercialization of Multiple Biosimilars in Japan
Samsung Bioepis expands its presence in Japanese market through partnership with NIPRO Corporation Marks a step forward in widening treatments options across multiple therapeutic areas including immunology for patients in Japan INCHEON, Korea, June 09, 2025--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. ("Samsung Bioepis") announced today that the company has entered into a license, development and commercialization agreement with NIPRO Corporation ("NIPRO") for multiple biosimilar candidates including SB17, ustekinumab biosimilar candidate, in Japan. Under the terms of the agreement, Samsung Bioepis will be responsible for the development, manufacture and supply of the medicines, while NIPRO will be responsible for commercialization of the medicines in Japan. "This partnership marks an important step towards expanding our footprint in Japan. Biosimilars have a great potential to bring cost savings and widen access to treatments for healthcare systems, providers, and patients in Japan. We look forward to collaborating with NIPRO, a company renowned for its high-quality medical devices and healthcare solutions, to accelerate access to treatments in the Japanese market," said Kyung-Ah Kim, President and Chief Executive Officer of Samsung Bioepis. "We will continue to advance our development platform and innovate access to treatments for healthcare systems, payers, physicians, and patients around the world." About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: and follow us on social media – LinkedIn, X. View source version on Contacts MEDIA CONTACT Anna Nayun Kim, Yoon Kim, Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
3 hours ago
- Yahoo
The Tastiest Side Dish At Panda Express Is Actually One Of The Healthiest Things On The Menu
Panda Express is practically synonymous with mall crawls and quick eats. If you're looking for low-carb fast food options that won't ruin your diet, the choices can seem few and far between; however, there are still a handful of nutritious dishes among Panda's offerings. Tasting Table set out to determine the definitive rankings of Panda Express' menu items and stumbled upon a runner-up to its ubiquitous orange chicken that packs a punch of lean, green deliciousness. Panda Express super greens are nothing short of heroic and can be ordered as a health-conscious side dish, entree, or kid's meal. Though fast food vegetables can seem like a gamble as far as taste and quality, the mix of kale, cabbage, and broccoli is tossed in a sauce that's been seasoned to perfection, providing nutritional benefits without skimping on the flavor. Per Tasting Table's assessment, the super greens maintain a balanced consistency between crisp and tender, and the garlic sauce is reminiscent of a home-cooked meal. The wholesome nutritional value offers 7 grams of dietary fiber and 9 grams of protein per 10-ounce serving, both of which help to promote gut health, longevity, and healthy muscles. The dish is also lower in sugar, fat, and sodium in comparison to the dishes you should think twice about ordering. Panda Express fans certainly echo this positive sentiment, praising the dish for its simplicity in preparation and big flavor. Read more: 13 Chinese Restaurant Chains, Ranked Worst To Best A thoughtful mix of green vegetables in a light and aromatic sauce, Panda Express super greens are not only a go-to order for Panda customers, but also for employees. Many have tried to suss out what it is about the sauce that makes it so crave-worthy, and the truth is actually much simpler than you might imagine. Whereas copycat recipes attempt to replicate the dish by sauteeing the veggies in a neutral oil, and tossing them with minced garlic, ginger, and soy sauce, Panda Express employees have mentioned the sauce is primarily made of a powdered vegetable soup mix diluted in oil with an additional pinch of salt and garlic in which the blanched vegetables are tossed. You can easily make your own version of the dish at home, though it will not taste exactly like the Panda Express menu item you know and love. Whether you're venturing out for a fast food treat or making your own veggie side dish, remember that the key to any healthy dish is keeping your ingredients simple and preparation methods effective. And the next time you're tossed between steamed rice and chow mein, try pivoting towards a greener alternative. You might find yourself pleasantly surprised. Read the original article on Tasting Table.
